[go: up one dir, main page]

EA033130B1 - Способы и композиции для улучшения когнитивной функции - Google Patents

Способы и композиции для улучшения когнитивной функции

Info

Publication number
EA033130B1
EA033130B1 EA201170571A EA201170571A EA033130B1 EA 033130 B1 EA033130 B1 EA 033130B1 EA 201170571 A EA201170571 A EA 201170571A EA 201170571 A EA201170571 A EA 201170571A EA 033130 B1 EA033130 B1 EA 033130B1
Authority
EA
Eurasian Patent Office
Prior art keywords
levetiracetam
subject
pharmaceutically acceptable
acceptable salt
cognitive function
Prior art date
Application number
EA201170571A
Other languages
English (en)
Other versions
EA201170571A1 (ru
Inventor
Михела Галлахер
Ребекка Хаберман
Мин Тен Кох
Original Assignee
Дзе Джонс Хопкинс Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Джонс Хопкинс Юниверсити filed Critical Дзе Джонс Хопкинс Юниверсити
Publication of EA201170571A1 publication Critical patent/EA201170571A1/ru
Publication of EA033130B1 publication Critical patent/EA033130B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение касается лечения возрастного когнитивного расстройства. В частности, изобретение касается способа лечения возрастного когнитивного расстройства у субъекта, нуждающегося в таком лечении или находящегося под риском возникновения такого расстройства, включающий введение указанному субъекту терапевтически эффективного количества ингибитора протеина 2А синаптических везикул (SV2A) или его фармацевтически приемлемой соли, где SV2A-ингибитор выбран из группы, включающей леветирацетам, селетрацетам и бриварацетам. Также изобретение касается применения фармацевтической композиции для улучшения когнитивной функции у субъекта с возрастным когнитивным расстройством или риском его возникновения, содержащей леветирацетам или его фармацевтически приемлемую соль, где леветирацетам или его фармацевтически приемлемая соль присутствуют в количестве 5-140 мг или в количестве 0,7-180 мг.
EA201170571A 2008-10-16 2009-10-16 Способы и композиции для улучшения когнитивной функции EA033130B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10584708P 2008-10-16 2008-10-16
US15263109P 2009-02-13 2009-02-13
US17553609P 2009-05-05 2009-05-05
PCT/US2009/005647 WO2010044878A1 (en) 2008-10-16 2009-10-16 Methods and compositions for improving cognitive function

Publications (2)

Publication Number Publication Date
EA201170571A1 EA201170571A1 (ru) 2011-12-30
EA033130B1 true EA033130B1 (ru) 2019-08-30

Family

ID=41403972

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170571A EA033130B1 (ru) 2008-10-16 2009-10-16 Способы и композиции для улучшения когнитивной функции

Country Status (12)

Country Link
US (5) US20100099735A1 (ru)
EP (2) EP2346500B1 (ru)
JP (3) JP5917148B2 (ru)
CN (2) CN107243007A (ru)
AU (1) AU2009303834B2 (ru)
BR (1) BRPI0920342A2 (ru)
CA (1) CA2740610C (ru)
DK (2) DK3260118T3 (ru)
EA (1) EA033130B1 (ru)
ES (2) ES2865504T3 (ru)
HK (2) HK1245099A1 (ru)
WO (1) WO2010044878A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5917148B2 (ja) 2008-10-16 2016-05-11 ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ 認知機能を改善するための方法および組成物
BR112013020283A2 (pt) * 2011-02-09 2016-07-19 Univ Johns Hopkins "uso de inibidor de proteína de vesícula sináptica 2a (sv2a), valproato, levetiracetam, brivarecetam e seletracetam no tratamento de deficiência cognitiva, bem como composição farmacêutica compreendendo os mesmos"
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
EP2968257A4 (en) * 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
EP3297611B1 (en) * 2015-05-22 2019-07-03 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
WO2017117569A1 (en) 2015-12-30 2017-07-06 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
EP3458049A1 (en) * 2016-05-20 2019-03-27 Institut Pasteur Methods of treating sepsis with synaptic vesicle 2a and/or 2b binding chemical entities
US10370561B2 (en) 2016-06-28 2019-08-06 Prc-Desoto International, Inc. Urethane/urea-containing bis(alkenyl) ethers, prepolymers prepared using urethane/urea-containing bis(alkenyl) ethers, and uses thereof
US11098222B2 (en) 2018-07-03 2021-08-24 Prc-Desoto International, Inc. Sprayable polythioether coatings and sealants
CN109892247B (zh) * 2019-04-19 2023-08-18 桂林医学院 一种猫参与的检测大鼠认知功能的实验装置
US20220354807A1 (en) * 2019-09-30 2022-11-10 Xiamen University Use of valeric acid derivative in treatment of down's syndrome
MX2023000405A (es) * 2020-07-10 2023-05-10 Agenebio Inc Combinaciones de agonistas del receptor a del acido gamma aminobutirico (gabaa) alfa 5 e inhibidores de la glicoproteina de vesicula sinaptica 2a (sv2a) y metodos de uso en el tratamiento del deterioro cognitivo.
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5886023A (en) * 1991-05-02 1999-03-23 Daiichi Pharmaceutical Co., Ltd. Agent for improving dementia
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
US20080076820A1 (en) * 2001-08-22 2008-03-27 Eiichi Otomo Method for treating neurodegeneration
WO2009109547A1 (en) * 2008-03-03 2009-09-11 Ucb Pharma, S.A. Pharmaceutical solutions, process of preparation and therapeutic uses

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1309692A (en) 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
IT1045043B (it) * 1975-08-13 1980-04-21 Isf Spa Derivati pirrolidinici
IT1075280B (it) * 1977-02-11 1985-04-22 Isf Spa Procedimento per la preparazione di derivati pirrolidinici
BE864269A (fr) * 1977-03-03 1978-06-16 Parke Davis & Co Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
ATE27T1 (de) * 1978-05-08 1981-04-15 Ucb Sa Lactam-n-essigsaeuren und ihre amide, verfahren zu ihrer herstellung und heilmittel, die sie enthalten
US4654370A (en) 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
US4372960A (en) * 1980-12-12 1983-02-08 Warner-Lambert Company Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators
FR2515179A1 (fr) * 1981-07-24 1983-04-29 Hoffmann La Roche Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique
IL67623A (en) * 1983-01-05 1984-09-30 Teva Pharma 1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it
IL72381A (en) 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
US4558070A (en) * 1983-10-26 1985-12-10 Abbott Laboratories Acid salts of valproic acid
GB8412358D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
US4668687A (en) * 1984-07-23 1987-05-26 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
JPS6222785A (ja) * 1985-07-23 1987-01-30 Sanwa Kagaku Kenkyusho:Kk 新規な２−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤
IT1190133B (it) * 1986-06-19 1988-02-10 Chiesi Farma Spa Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE3709230A1 (de) * 1987-03-20 1988-10-06 Desitin Arzneimittel Gmbh Neues calciumsalz der valproinsaeure
JPS6422883A (en) * 1987-07-17 1989-01-25 Sanwa Kagaku Kenkyusho Co 1-pyrrolidine acetamide derivative, its salt, production thereof and prophylactic and remedial agent for cereral dysfunction containing said derivative and salt as active ingredient
EP0300111B1 (en) * 1987-07-22 1991-10-16 Farvalsa AG A moisture stable solid valproic acid formulation and a method of preparing the same
CA2007732A1 (en) 1989-01-17 1990-07-17 Gary L. Olson Cyclohexaneacetamide derivatives
FR2643556B1 (fr) 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
IT1231477B (it) * 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
US5439930A (en) * 1992-04-14 1995-08-08 Russian-American Institute For New Drug Development Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
US5440023A (en) * 1992-09-18 1995-08-08 Beckman Instruments, Inc. Method for making valproic acid derivatives
GB9319732D0 (en) * 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
US5468733A (en) 1993-09-30 1995-11-21 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5516759A (en) 1994-12-08 1996-05-14 Tap Holdings Inc. LHRH antagonists having lactam groups at the N-terminus
IT1285801B1 (it) 1996-10-10 1998-06-24 Sigma Tau Ind Farmaceuti Procedimento migliorato per la preparazione dell'acido valproico
US6131106A (en) 1998-01-30 2000-10-10 Sun Microsystems Inc System and method for floating-point computation for numbers in delimited floating point representation
US6620802B1 (en) * 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
CA2392879C (en) 1999-12-01 2005-03-29 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
ATE431142T1 (de) * 2000-12-28 2009-05-15 Hamilton Pharmaceuticals Inc Arzneimittel zur behandlung und vermeidung neurogener schmerzen
US6610326B2 (en) * 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
EP1379236A4 (en) * 2001-02-23 2009-01-21 Ucb Sa TREATMENT OF TICS, TREMORS AND RELATED DISORDERS
EP1395560A1 (en) 2001-05-23 2004-03-10 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
KR20090080573A (ko) 2001-10-16 2009-07-24 메모리 파마슈티칼스 코포레이션 신경계 증후군의 치료를 위한 ｐｄｅ-4 억제제로서의 4-(4-알콕시-3-히드록시페닐)-2-피롤리돈 유도체
US20040116506A1 (en) * 2002-06-20 2004-06-17 Krusz John Claude Use of levetiracetam for treating or preventing acute headaches
US7557137B2 (en) * 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
US7090985B2 (en) * 2002-12-03 2006-08-15 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
US20070135514A1 (en) * 2002-12-03 2007-06-14 Berkley Lynch Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
ITMI20030573A1 (it) * 2003-03-24 2004-09-25 Nikem Research Srl Composti ad azione nootropica, loro preparazione,
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
ES2323313T3 (es) 2003-12-02 2009-07-13 Ucb Pharma, S.A. Derivados de imidazol, procedimientos para prepararlos y sus usos.
JP2007533741A (ja) 2004-04-22 2007-11-22 イーライ リリー アンド カンパニー Ｂａｃｅ阻害剤
DE602005003472T2 (de) 2004-06-11 2008-09-25 Ucb Pharma, S.A. Verfahren zur herstellung von 2-oxo-1-pyrrolidinderivaten durch intramolekulare allylierung
NZ556630A (en) * 2005-01-27 2010-12-24 Alembic Ltd Extended release formulation of levetiracetam including a hydrophilic rate controlling polymer
AU2006228947A1 (en) * 2005-03-30 2006-10-05 Mylan Pharmaceuticals Ulc Combined-step process for pharmaceutical compositions
CA2610695A1 (en) 2005-06-01 2006-12-07 Ucb Pharma, S.A. 2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system
GB0517740D0 (en) 2005-08-31 2005-10-12 Novartis Ag Organic compounds
AU2006322349A1 (en) 2005-12-07 2007-06-14 Ucb Pharma, S.A. Xanthine derivatives, processes for preparing them and their uses
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) * 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US20080014264A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
WO2008132139A2 (en) 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
KR20090031333A (ko) 2007-09-21 2009-03-25 주식회사 엘지생명과학 신규한 베타-세크리타제 저해용 화합물
US20090176740A1 (en) 2007-11-30 2009-07-09 Phillips Ii Dauglas James Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
JP2010024156A (ja) 2008-07-16 2010-02-04 Ucb Pharma Sa レベチラセタムを含む医薬組成物
JP2011529923A (ja) 2008-08-06 2011-12-15 ゴスフォース センター（ホールディングス）プロプライエタリー リミテッド 精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法
JP5917148B2 (ja) 2008-10-16 2016-05-11 ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ 認知機能を改善するための方法および組成物
US9125898B2 (en) * 2008-11-14 2015-09-08 Neurotune Ag Acetam derivatives for pain relief
CA2741041C (en) 2008-11-18 2015-01-13 Ucb Pharma S.A. Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative
PL2391351T3 (pl) 2009-01-29 2015-02-27 Ucb Pharma Sa Kompozycje farmaceutyczne zawierające pochodne 2-okso-1-pirolidyny
EP2393483B1 (en) 2009-02-09 2017-06-28 UCB Biopharma SPRL Pharmaceutical compositions comprising brivaracetam
WO2011015349A2 (en) 2009-08-07 2011-02-10 Ucb Pharma, S.A. Methods for enhancing the cognitive function

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5886023A (en) * 1991-05-02 1999-03-23 Daiichi Pharmaceutical Co., Ltd. Agent for improving dementia
US20080076820A1 (en) * 2001-08-22 2008-03-27 Eiichi Otomo Method for treating neurodegeneration
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
WO2009109547A1 (en) * 2008-03-03 2009-09-11 Ucb Pharma, S.A. Pharmaceutical solutions, process of preparation and therapeutic uses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"P.5.017 Use of valproate in treatment of behavioural and psychological disturbances of dementia", EUROPEAN NEUROPSYCHOPHARMACOLOGY., ELSEVIER SCIENCE PUBLISHERS BV, AMSTERDAM., NL, vol. 15, 1 January 2005 (2005-01-01), NL, pages S565, XP025327109, ISSN: 0924-977X *
LIPPA CAROL; REVUELTA GONZALO; GLIEBUS GEDIMINAS; IRWIN DAVID; TOWNSHIP HADDON; HEPLER MARJORIE; ROSSO ANDREA: "Levetiracetam: Seizure management for elderly patients with cognitive impairment", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 70, no. 11, suppl. 1, 11 March 2008 (2008-03-11), US, pages A97, XP009127253, ISSN: 0028-3878 *
MARINI G; CARATTI C; PELUFFO F; CELASCO G; GASPARRO M G: "PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF PRAMIRACETAM CI-879 IN THE TREATMENT OF ELDERLY SUBJECTS WITH MEMORY IMPAIRMENT", ADVANCES IN THERAPY., HEALTH COMMUNICATIONS, METUCHEN, NJ., US, vol. 9, no. 3, 1 January 1992 (1992-01-01), US, pages 136 - 146, XP009127252, ISSN: 0741-238X *
ROZZINI R; ZANETTI O; BIANCHETTI A: "Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy.", ACTA NEUROLOGICA, CHIRURGIA, NAPLES, IT, vol. 15, no. 1, 1 February 1993 (1993-02-01), IT, pages 44 - 52, XP009127254, ISSN: 0001-6276 *

Also Published As

Publication number Publication date
EA201170571A1 (ru) 2011-12-30
CN102227217A (zh) 2011-10-26
JP6271641B2 (ja) 2018-01-31
EP2346500B1 (en) 2017-05-17
US20120046336A1 (en) 2012-02-23
CA2740610C (en) 2020-01-07
JP2016147915A (ja) 2016-08-18
CN107243007A (zh) 2017-10-13
DK3260118T3 (da) 2021-04-19
US20240293363A1 (en) 2024-09-05
EP2346500A1 (en) 2011-07-27
US20100099735A1 (en) 2010-04-22
JP2014169339A (ja) 2014-09-18
ES2865504T3 (es) 2021-10-15
EP3260118A1 (en) 2017-12-27
EP3260118B1 (en) 2021-03-24
AU2009303834B2 (en) 2016-08-11
CA2740610A1 (en) 2010-04-22
BRPI0920342A2 (pt) 2020-06-23
HK1245099A1 (zh) 2018-08-24
JP5917148B2 (ja) 2016-05-11
DK2346500T3 (en) 2017-07-17
AU2009303834A1 (en) 2010-04-22
US20150094352A1 (en) 2015-04-02
US20220218665A1 (en) 2022-07-14
JP2012505883A (ja) 2012-03-08
US8604075B2 (en) 2013-12-10
ES2637497T3 (es) 2017-10-13
HK1248543A1 (zh) 2018-10-19
WO2010044878A1 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
EA033130B1 (ru) Способы и композиции для улучшения когнитивной функции
GEP20125565B (en) Lactam compounds and their pharmaceutical use
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
WO2007112000A3 (en) Treatment of pain
ATE417832T1 (de) Hexahydrodiazepinone als inhibitoren des dipeptidylpeptidase-iv zur behandlung bzw. prävention von diabetes
ATE473742T1 (de) Kondensierte triazolderivate als dipeptidylpeptidase-iv-hemmer zur behandlung bzw. prävention von diabetes
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
MY161991A (en) Proteasome inhibitors
EP1673078A4 (en) BENZYL ETHER AND BENZYLAMINO BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
EA200900662A1 (ru) Лечение синдрома "сухого глаза" с помощью тестостерона и прогестагена
DK1885333T3 (da) Farmaceutisk formulering af apomorphin til bukkal indgivelse
HRP20050262A2 (en) Pyrrolidone derivatives as maob inhibitors
MA30296B1 (fr) Nouvelles amines
EA200800011A1 (ru) Тиенопиримидиновые и тиенопиридиновые модуляторы киназы
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
DE60233433D1 (de) PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN
MA30292B1 (fr) Amines primaires comme inhibiteurs de la renine
DE602004015089D1 (de) Pyrroloimidazolderivate ,verfahern zu ihrer herstellung, diese enthaltende zusammensetzungen, und ihre verwendung als nootropika
EA200601687A1 (ru) Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1
EA200600316A1 (ru) ПРОИЗВОДНЫЕ 3-НИТРОПИРАЗОЛО[1,5-a]ПИРИМИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИСПОЛЬЗУЕМЫЕ В НЕМ ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), ЛЕКАРСТВЕННОЕ СРЕДСТВО (ВАРИАНТЫ) И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ РЕЦЕПТОРА ГАМК(ВАРИАНТЫ)
MXPA05009242A (es) Tratamiento de la diabetes tipo 1 con los inhibidores de la pde5.
TW200621773A (en) Bicyclononene derivatives

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG MD TJ TM